Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody

References

• Pardee AB. G1 events and regulation of cell proliferation. Science 1989; 246:603-8; PMID:2683075; http://dx.doi.org/10.1126/science.2683075
   PubMed Web of Science ®Google Scholar
• Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996; 84:359-69; PMID:8608589; http://dx.doi.org/10.1016/S0092-8674(00)81280-5
   PubMed Web of Science ®Google Scholar
• Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270:1326-31; PMID:7481820; http://dx.doi.org/10.1126/science.270.5240.1326
   PubMed Web of Science ®Google Scholar
• Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305:1163-7; PMID:15284455; http://dx.doi.org/10.1126/science.1101637
   PubMed Web of Science ®Google Scholar
• Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19:3159-67; PMID:10880430; http://dx.doi.org/10.1093/emboj/19.13.3159
   PubMed Web of Science ®Google Scholar
• Plati J, Bucur O, Khosravi-Far R. Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities. J Cell Biochem 2008; 104:1124-49; PMID:18459149; http://dx.doi.org/10.1002/jcb.21707
   PubMed Web of Science ®Google Scholar
• Spreter Von Kreudenstein T, Lario PI, Dixit SB. Protein engineering and the use of molecular modeling and simulation: The case of heterodimeric Fc engineering. Methods 2014; 65:77-94; PMID:24211748; http://dx.doi.org/10.1016/j.ymeth.2013.10.016
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92; PMID:11248153; http://dx.doi.org/10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Hudson PJ. Recombinant antibody constructs in cancer therapy. Curr Opin Immunol 1999; 11:548-57; PMID:10508712; http://dx.doi.org/10.1016/S0952-7915(99)00013-8
   PubMed Web of Science ®Google Scholar
• Fitzgerald J, Lugovskoy A. Rational engineering of antibody therapeutics targeting multiple oncogene pathways. mAbs 2011; 3:299-309; PMID:21393992; http://dx.doi.org/10.4161/mabs.3.3.15299
   PubMed Web of Science ®Google Scholar
• Kontermann R. Dual targeting strategies with bispecific antibodies. Mabs 2012; 4(2):182-197; PMID:22327426; http://dx.doi.org/10.4161/mabs.4.2.19000
   PubMedGoogle Scholar
• Garber K. Bispecific antibodies rise again. Nat Rev Drug Dis 2014; 13:799-801; PMID:25359367; http://dx.doi.org/10.1038/nrd4478
   PubMed Web of Science ®Google Scholar
• McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Therapeut 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11-0820
   PubMed Web of Science ®Google Scholar
• Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Therapeut 2014; 13:410-25; PMID:24282274; http://dx.doi.org/10.1158/1535-7163.MCT-13-0255
   PubMed Web of Science ®Google Scholar
• Kamath AV, Lu D, Gupta P, Jin D, Xiang H, Wong A, Leddy C, Crocker L, Schaefer G, Sliwkowski MX, et al. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 2012; 69:1063-9; PMID:22203367; http://dx.doi.org/10.1007/s00280-011-1806-6
   PubMed Web of Science ®Google Scholar
• Seimetz D, Lindhofer H, Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010; 36:458-67; PMID:20347527; http://dx.doi.org/10.1016/j.ctrv.2010.03.001
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, Horst HA, Raff T, Viardot A, Schmid M, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-8; PMID:21576633; http://dx.doi.org/10.1200/JCO.2010.32.7270
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Recombinant bispecific antibodies for cancer therapy. Acta Pharmacologica Sinica 2005; 26:1-9; PMID:15659107; http://dx.doi.org/10.1111/j.1745-7254.2005.00008.x
   PubMed Web of Science ®Google Scholar
• Rouet R, Christ D. Bispecific antibodies with native chain structure. Nat Biotechnol 2014; 32:136-7; PMID:24509759; http://dx.doi.org/10.1038/nbt.2812
   PubMed Web of Science ®Google Scholar
• Lewis SM, Wu X, Pustilnik A, Sereno A, Huang F, Rick HL, Guntas G, Leaver-Fay A, Smith EM, Ho C, et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol 2014; 32:191-8; PMID:24463572; http://dx.doi.org/10.1038/nbt.2797
   PubMed Web of Science ®Google Scholar
• Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nature Rev Immun 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A 2013; 110:5145-50; PMID:23479652; http://dx.doi.org/10.1073/pnas.1220145110
   PubMed Web of Science ®Google Scholar
• Lauffenburger DA, Linderman J. Receptors: Models for Binding, Trafficking, and Signaling Oxford University Press, Oxford, United Kingdom
   Google Scholar
• McCloskey N, Turner MW, Goldblatt TD. Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). J Immunol Methods 1997; 205:67-72; PMID:9236916; http://dx.doi.org/10.1016/S0022-1759(97)00059-8
   PubMed Web of Science ®Google Scholar
• Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharmaceut 2009; 24:155-61; PMID:19409036; http://dx.doi.org/10.1089/cbr.2009.0627
   PubMed Web of Science ®Google Scholar
• Harms BD, Kearns JD, Su SV, Kohli N, Nielsen UB, Schoeberl B. Chapter four - Optimizing Properties of Antireceptor Antibodies Using Kinetic Computational Models and Experiments. In: Wittrup KD, Gregory LV, eds. Methods Enzymol: Academic Press, 2012:67-87.
   Google Scholar
• Harms BD, Kearns JD, Iadevaia S, Lugovskoy AA. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods 2014; 65:95-104; PMID:23872324; http://dx.doi.org/10.1016/j.ymeth.2013.07.017
   PubMed Web of Science ®Google Scholar
• Moores, SL, Chiu M, Bushey B, Chevalier K, Haytko P, Neijssen, J, Parren, P, Schuurman J, Anderson M, Attar R, et al. Discovery and preclinical pharmacology of JNJ-61186372: A novel bispecific antibody targeting EGFR and cMET. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5–9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr DDT01-03. doi:10.1158/1538-7445.AM2014-DDT01-03.
   Google Scholar
• Jarantow SW, Bushey B, Pardinas JR, Boakye K, Lacy E, Sanders R, Sepulveda MA, Moores SL, Chiu ML. Impact of Cell-Surface Antigen Expression on Target Engagement and Function of an EGFR x c-Met Bispecific Antibody. J Biol Chem 2015; 290: 24689-24704; PMID:26260789; http://dx.doi.org/10.1074/jbc.M115.651653
   PubMed Web of Science ®Google Scholar
• Schuurman J, W.H.I. Parren P. Mind the gap. Methods 2014; 65:1-4; PMID:24184353; http://dx.doi.org/10.1016/j.ymeth.2013.10.012
   PubMed Web of Science ®Google Scholar
• Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? mAbs 2009; 1:539-47; PMID:20073127; http://dx.doi.org/10.4161/mabs.1.6.10015
   PubMed Web of Science ®Google Scholar
• Nunez-Prado N, Compte M, Harwood S, Alvarez-Mendez A, Lykkemark S, Sanz L, Álvarez-Vallina L. The coming of age of engineered multivalent antibodies. Drug Dis Today 2015; 20:588-94; PMID:25757598; http://dx.doi.org/10.1016/j.drudis.2015.02.013
   PubMed Web of Science ®Google Scholar
• Ruiz-Herrero T, Estrada J, Guantes R, Miguez DG. A Tunable Coarse-Grained Model for Ligand-Receptor Interaction. PLoS Comput Biol 2013; 9:e1003274; PMID:24244115; http://dx.doi.org/10.1371/journal.pcbi.1003274
   PubMedGoogle Scholar
• Krzyzanski W. Systems pharmacology models for guiding drug design. CPT: Pharmacometrics Systems Pharmacol 2013; 2:e39; http://dx.doi/org/10.1038/psp.2013.15
   Google Scholar
• Moores S, Chiu M, Bushey B, Chevalier K, Chin D, Chippari S, Haytko P, McCabe F, Neijssen J, Parren P, et al. Bispecific antibody targeting EGFR and cMet demonstrates superior activity compared to the combination of single pathway inhibitors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19–23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl): Abstract nr B241.
   Google Scholar
• Robinson MK, Hodge KM, Horak E, Sundberg AL, Russeva M, Shaller CC, von Mehren M, Shchaveleva I, Simmons HH, Marks JD, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99:1415-25; PMID:18841159; http://dx.doi.org/10.1038/sj.bjc.6604700
   PubMed Web of Science ®Google Scholar
• Dong J, Sereno A, Aivazian D, Langley E, Miller BR, Snyder WB, Chan E, Cantele M, Morena R, Joseph IB, Boccia A, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. mAbs 2011; 3:273-88; PMID:21393993; http://dx.doi.org/10.4161/mabs.3.3.15188
   PubMed Web of Science ®Google Scholar
• Iyer SB, Hultin LE, Zawadzki JA, Davis KA, Giorgi JV. Quantitation of CD38 expression using QuantiBRITE beads. Cytometry 1998; 33:206-12; PMID:9773881; http://dx.doi.org/10.1002/(SICI)1097-0320(1998-1001)33:2%3c206::AID-CYTO15%3e3.0.CO;2-Y
   PubMedGoogle Scholar
• Pannu KK, Joe ET, Iyer SB. Performance evaluation of QuantiBRITE phycoerythrin beads. Cytometry 2001; 45:250-8; PMID:11746094; http://dx.doi.org/10.1002/1097-0320(20011201)45:4%3c250::AID-CYTO10021%3e3.0.CO;2-T
   PubMedGoogle Scholar
• Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res 2010; 16:174-83; PMID:20008840; http://dx.doi.org/10.1158/1078-0432.CCR-09-1204
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Therap 2012; 11:2149-57; PMID:22844075; http://dx.doi.org/10.1158/1535-7163.MCT-12-0195
   PubMed Web of Science ®Google Scholar
• Shah DK, Haddish-Berhane N, Betts A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin. J Pharmacokinet Pharmacody 2012; 39:643-59; PMID:23151991; http://dx.doi.org/10.1007/s10928-012-9276-y
   PubMed Web of Science ®Google Scholar
• Mac Gabhann F, Yang MT, Popel AS. Monte Carlo simulations of VEGF binding to cell surface receptors in vitro. Biochim Biophys Acta 2005; 1746:95-107; PMID:16257459; http://dx.doi.org/10.1016/j.bbamcr.2005.09.004
   PubMed Web of Science ®Google Scholar